Chimeric TGFB Signaling Receptor (CTSR) Enabled Anti-B7H3 CAR T-cell Therapy in Children and AYA with Recurrent Solid Tumors

Return to Grants

Grant Award Details

Grant Number:
CLIN1-15337
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$6,000,000
Status:
Active

Grant Application Details

Application Title:

Chimeric TGFB Signaling Receptor (CTSR) Enabled Anti-B7H3 CAR T-cell Therapy in Children and AYA with Recurrent Solid Tumors

Public Abstract:
Therapeutic Candidate or Device

Engineered CAR T-cells are enhanced to allow their survival in solid tumors

Indication

Children, adolescents and young adults with variety of solid tumors but focus on sarcomas and neuroblastomas

Therapeutic Mechanism

Engineered T-cells are expanded and infused back to the patients. The additional mechanisms engineered in these cells allows them to survive in the hostile environment of a solid tumor and kill the tumor cells.

Unmet Medical Need

The survival of children and young adults with metastatic sarcomas has not significantly changed over the last 40 years. The young children and adults also have significant morbidity due to the toxic effects of current standard therapies (e.g. chemotherapy, radiation therapy)

Project Objective

Submission of Phase 1 trial IND

Major Proposed Activities

  • Generate the virsues needed to engineer the T-cells
  • Establish the processes to make the engineered T-cells for patients
  • Establish the protocols and regulatory documents to conduct the trial and apply for FDA approval
Statement of Benefit to California:
The engineered T-cells we are proposing could significantly help children and young adults living in California with devastating diagnosis of cancers affecting their bones and muscles. If successful , this therapy could also benefit other adult solid tumors.